(NASDAQ: VTVT) Vtv Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.9%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.76%.
Vtv Therapeutics's earnings in 2026 is -$7,678,000.On average, 9 Wall Street analysts forecast VTVT's earnings for 2026 to be -$4,689,001, with the lowest VTVT earnings forecast at -$6,447,227, and the highest VTVT earnings forecast at -$1,684,815. On average, 9 Wall Street analysts forecast VTVT's earnings for 2027 to be -$17,028,268, with the lowest VTVT earnings forecast at -$25,081,284, and the highest VTVT earnings forecast at -$10,361,614.
In 2028, VTVT is forecast to generate -$18,625,232 in earnings, with the lowest earnings forecast at -$27,125,526 and the highest earnings forecast at -$14,742,134.